Secondary cardiovascular prevention guidelines emphasize stringent lipid targets to mitigate recurrent vascular events. However, the specific clinical value of relative percentage lowering versus absolute target attainment remains debated in cerebrovascular disease. A landmark nationwide study has now evaluated the long-term clinical utility of ischemic stroke LDL reduction, demonstrating that achieving a relative drop of at least 50% from baseline substantially reduces major vascular complications.

Dual Goals in Ischemic Stroke LDL Reduction Guidelines

Current international guidelines for atherosclerotic cardiovascular disease outline two primary targets for secondary prevention: achieving an absolute low-density lipoprotein cholesterol level below 70 mg/dL and securing a relative reduction of at least 50% from baseline. In cardiology practice, clinicians routinely enforce both metrics. Conversely, stroke-specific management algorithms have historically focused primarily on absolute numerical targets.

This divergence in clinical practice has created ambiguity regarding whether relative percentage reductions confer independent protective value for stroke survivors. Many stroke patients present with relatively modest baseline cholesterol concentrations. Consequently, these individuals may achieve an absolute target of under 70 mg/dL with only minimal or moderate percentage reductions. Until now, longitudinal evidence confirming whether failing to achieve the relative 50% reduction increases recurrence risk has remained scarce. Therefore, establishing clarity on this topic provides vital direction for post-stroke lipid management across clinical specialties.

Evaluating Long-Term Outcomes in the Korean Cohort

To resolve this clinical question, investigators analyzed nationwide data from the Korean National Health Insurance Service database between 2014 and 2022. The retrospective cohort study evaluated 89,414 adult patients who suffered an acute ischemic stroke and underwent serial national health examinations. Researchers tracked 136,427 post-stroke lipid measurements over a mean follow-up duration of 5.72 years.

Patients were stratified into four distinct categories based on their longitudinal lipid trajectories: those achieving both an absolute level under 70 mg/dL and a relative reduction of at least 50%, those achieving the absolute target alone, those reaching only the relative reduction, and those failing both targets. The investigators examined a primary composite outcome comprising recurrent stroke, myocardial infarction, and all-cause mortality using time-varying Cox proportional hazards regression models. Furthermore, the researchers conducted extensive subgroup analyses stratified by age, sex, baseline lipid levels, and stroke etiology.

Prognostic Significance of Relative Percentage Lowering

The findings revealed significant prognostic divergence across the patient cohorts. Overall, only about 30% of stroke survivors consistently achieved the dual goal of a 50% or greater relative reduction throughout follow-up. When compared against the optimal reference group—patients achieving both under 70 mg/dL and a 50% or greater reduction—patients who failed to attain the 50% relative reduction faced significantly elevated cardiovascular risks.

Specifically, patients who achieved an absolute level below 70 mg/dL but missed the 50% relative reduction exhibited a 12% increased risk of composite adverse events. Moreover, individuals who missed both targets experienced a 28% higher risk. Similar adverse trends occurred when applying the more aggressive threshold of 55 mg/dL. These associations remained robust regardless of baseline cholesterol levels or presumed cardioembolic mechanisms. Thus, relative percentage reduction provides substantial prognostic protection independent of absolute concentration.

Mechanistic Insights and Atherosclerotic Plaque Stability

The physiological rationale supporting aggressive relative reduction centers on vascular biology and plaque stabilization. High-intensity lipid-lowering therapy alters atheroma composition beyond merely lowering circulating lipid concentrations. When patients experience a substantial percentage reduction in low-density lipoproteins, plaque volume regresses and the fibrous cap thickens. Consequently, vulnerable intracranial and extracranial atherosclerotic plaques become far more stable.

In addition, profound lipid reduction reduces systemic vascular inflammation and improves endothelial function. In patients with lower baseline cholesterol, reaching an absolute number without substantial percentage lowering often reflects mild lipid therapy rather than true disease modification. Therefore, achieving a steep drop depletes circulating atherogenic particles and halts progressive vessel stenosis. These cellular mechanisms explain why relative lipid drops deliver profound clinical benefits in secondary neurovascular prevention.

Clinical Implications for Multidisciplinary Stroke Management

These observational findings provide critical implications for clinical practice across neurology, cardiology, and general medicine. Clinicians can no longer rely solely on static lipid cutoffs when discharging stroke patients. Instead, treatment teams must calculate baseline lipid parameters promptly during acute hospital admission and tailor medical regimens accordingly.

To ensure patients attain at least a 50% relative drop, clinicians should initiate high-intensity statin therapy immediately unless contraindicated. Furthermore, physicians should maintain a low threshold for adding non-statin therapies, such as ezetimibe or PCSK9 inhibitors, when statins alone prove insufficient. Routine follow-up lipid panels at four to twelve weeks allow practitioners to verify relative reductions and intensify therapies promptly. By adopting this dual-target strategy, clinicians can substantially mitigate the persistent risk of recurrent ischemic events and long-term mortality.

Summary and Future Directions in Lipid Optimization

In summary, optimal secondary stroke prevention requires aggressive, comprehensive lipid optimization. Relying exclusively on absolute cholesterol levels leaves a substantial portion of stroke survivors under-treated and vulnerable to recurrent vascular catastrophe. Integrating both relative percentage reduction and absolute numerical targets bridges an essential gap between cardiology standards and neurological care.

Future randomized prospective trials will further clarify optimal therapeutic combinations and thresholds for specific stroke subtypes. Meanwhile, current evidence strongly supports a more proactive, intensive lipid-lowering strategy in routine stroke rehabilitation pathways. Healthcare providers must monitor post-stroke lipid trajectories continuously and escalate lipid-lowering regimens systematically to ensure durable clinical protection.

Frequently Asked Questions

Why is a 50% reduction in LDL cholesterol necessary after an ischemic stroke?

A relative reduction of at least 50% from baseline promotes vascular plaque stabilization and reduces systemic inflammation. Research shows that patients who fail to achieve this relative reduction face a significantly higher risk of recurrent stroke, myocardial infarction, and death, even if their absolute cholesterol level drops below 70 mg/dL.

How should clinicians treat stroke patients who already have low baseline LDL levels?

Even when patients present with low baseline cholesterol, clinicians should still prescribe high-intensity lipid-lowering therapy. Reaching an absolute threshold without achieving a significant percentage drop does not provide maximal plaque regression. Therefore, physicians should aim to reduce baseline cholesterol by half to optimize long-term secondary prevention outcomes.

Which therapeutic strategies help stroke patients achieve both relative and absolute lipid targets?

Clinicians should initiate high-intensity statin therapy, such as atorvastatin or rosuvastatin, immediately following an acute ischemic stroke. If the four-to-twelve-week follow-up lipid panel reveals inadequate reduction, physicians should promptly add ezetimibe or PCSK9 inhibitors to achieve both a 50% reduction and an absolute target under 70 mg/dL.

Disclaimer: This content is for informational and educational purposes only and is intended solely for healthcare professionals. It does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should always be based on the independent judgment of the treating physician, considering individual patient circumstances, established clinical practice guidelines, and relevant medical literature. Product mentions, if any, do not imply endorsement. Refer to the latest local and national guidelines for clinical practice.

References

Baik M et al. Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke. Neurology. 2026 Sep 22. doi: 10.1212/WNL.0000000000218491. PMID: 42623575.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.

Amarenco P, Kim JS, Labreuche J, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020;382(1):9-19.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.